

Welcome

It is a pleasure to welcome you to *IP in the Life Sciences Industries 2009*, a special supplement of *Intellectual Asset Management* magazine.

Intellectual property is one of the most important assets owned by companies operating in the life sciences industries today. An appreciation of the importance of IP must begin at the company's inception, well before the R&D begins. Whether a multinational pharmaceutical manufacturer, a biotech business preparing for an IPO or an early-stage university spin-out, the company's IP portfolio is crucial to its future success. This is only too obvious when one looks at the share movements triggered by the rulings in some major patent-related lawsuits.

An understanding of how best to build, manage and protect your IP is essential to a successful corporate strategy, and something that every senior executive working in the life sciences industries should possess. Collaboration, and the large investments of time and money made by companies during the R&D process, leave them vulnerable to grave financial loss unless they have a coherent IP strategy. For example, without the protection that IP rights provide, the huge investment required for the drug discovery process could not be justified.

However, building a patent portfolio is not the only way that a company in the life sciences industry can seek to benefit from its intellectual property. A thorough understanding of IP can help a company to ensure that its R&D expenditure is not wasted on areas already saturated with patent-clusters, and aid it in identifying less crowded potential avenues of research.

Furthermore, while the acquisition of

intellectual property is often one of the main motivating forces behind M&A deals in the life sciences sector, those with a sound appreciation of IP will dig deeper into a target company's portfolio to unearth any major flaws or weaknesses and potential bargaining tools. Equally, a strong roster of rights makes a company less vulnerable to litigation by affording an opportunity to settle disputes through cross-licensing. Sometimes, however, the courts are unavoidable. In these instances, a thorough understanding of the litigation process is crucial, as a wrong turn can end up costing hundreds of millions of dollars and prove crippling for a company.

It is with all this in mind, and more, that we have put together *IP in the Life Sciences Industries 2009*. This unique publication is designed to highlight, in a practical and business-focused way, some of the major IP issues facing life sciences executives and the people – such as VCs and other investors – with whom they deal.

To ensure the quality of the product, those contributing to *IP in the Life Sciences Industries 2009* were invited to participate because of their acknowledged expertise in the field. This expert team of private practice lawyers identify and then explain some of the key legal issues that parties in the life sciences industries will face as they move through the commercialisation process. I hope you agree that with the help of all of our contributors, we have produced something that provides concise, relevant information that will be of constant value.

Sara-Jayne Adams
Reporter, *IAM* magazine

Editorial board

Bruce Berman
President, Brody Berman Associates
Douglas R Elliott
Founder and CEO,
TEQ Development LLC
Scott Frank
President,
AT&T Intellectual Property
Bruce Lehman
Chairman of the International
Intellectual Property Institute
Daniel M McGavock
Vice President and Global IP Practice
Leader, CRA International
Ruud Peters
CEO Philips IP & Standards
Marshall Phelps
Corporate Vice President for
Intellectual Property, Microsoft Corp.
Herbert C Wamsley
Executive Director, Intellectual
Property Owners Association
Rob Willows
Vice President, Thomson Scientific
Industrial Property Markets Division

Editor

Joff Wild
jwild@iam-magazine.com

Finance editor

Nigel Page
npage@iam-magazine.com

Contributing editors

Richard Marsland
rmarsland@iam-magazine.com

Adrian Preston
apreston@iam-magazine.com

Reporter

Sara-Jayne Adams
sadams@iam-magazine.com

Sub-editor

Carolyn Boyle
cboyle@iam-magazine.com

Design and production

Russell Anderson
John Meikle

Subscriptions and marketing manager

Alan Mowat
amowat@theipmediagroup.com

Circulation

Amanda Green
agreen@iam-magazine.com

Antonio Ignatius

Associate publishers

John Eborall
jeborall@theipmediagroup.com

David House
dhouse@theipmediagroup.com

Nicholas House
nhouse@theipmediagroup.com

Group publisher

Gavin Stewart
gstewart@theipmediagroup.com

Publishing director

Tony Harriss
tharriss@iam-magazine.com

Globe White Page Ltd

New Hibernia House
Winchester Walk
London SE1 9AG, UK

Tel +44 20 7234 0606

Fax +44 20 7234 0808

Email info@iam-magazine.com

Web www.iam-magazine.com

IP in the life sciences industries 2009 is a free supplement to *IAM* magazine. Contact Alan Mowat at amowat@ipmediagroup.com to subscribe to *IAM* magazine.

Part of  **The IP Media Group**

ISSN 1741-1424

Individual subscription rate GB£435

Printing and origination by
Pyramid Press, Nottingham, UK

© **Globe White Page Ltd**

Copyright applies. No photocopying.
For licensed photocopying please
call +44 20 7234 0606

This publication does not
purport to provide investment advice.
The publishers do not bear the
responsibility for any errors or
omissions contained in the magazine.